Exchange: NASDAQ·Updated 04:56 PM EDT
MYGN logo

MYGNMyriad Genetics, Inc.

$5.61
$0.09
(1.58%)
Today
Closed $5.61
$0.08
(1.43%)
After Hours
EarningsJul 30
Mkt Cap$529.85M
Vol867,630.00
News
all
press releases
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Zacks
More News
AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now?
Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in.
Zacks
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?
Zacks
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Zacks
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Zacks
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Zacks
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Zacks
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
Zacks
<
1
2
...
>

Advertisement|Remove ads.